Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis
A Randomized Clinical Trial
Abstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory joint disorder with unknown etiology. Atorvastatin is a lipid-lowering agent that affects the inflammatory processes.
Objective: This study aimed to determine the anti-inflammatory effects of atorvastatin on the Disease Activity Index and high-density lipoprotein (HDL) concentrations in RA patients.
Methods: This clinical trial was performed on 38 RA patients, who were referred to the Imam Reza and Ghaem Medical Centers of Mashhad, Iran between 2013 and 2014. Patients were divided into two groups: 1) the intervention group, which received 40 mg of atorvastatin, and 2) the control group. Response to treatment and the clinical status of patients were evaluated using the Disease Activity Score (DAS-28) and Visual Analogue Scale (VAS) at weeks zero, four, eight, and twelve, based on the 2010 ACR/EULAR Criteria by two rheumatologists. Disease activity and laboratory parameters, including erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), DAS-ESR, DAS- hs-CRP, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and liver function test (LFT) were measured in both groups.
Results: There was a significant difference in the mean number of swollen joints (p<0.011), ESR (p <0.005), DAS-ESR (P<0.043), LDL (0.036), and HDL (0.016) between the two groups. The changes in trend showed no significant difference in the mean number of tender joints (p =0.38), VAS (p =0.715), CRP (p =0.07), DAS-hs-CRP (p=0.431), total cholesterol (p=0.285), or TG (p =0.331) between the two groups. However, the Disease Activity Index decreased by 48.4% in the intervention group, compared to 35.5% in the control group.
Conclusion: As the results indicated, atorvastatin has a positive effect on the course of RA. In fact, atorvastatin, as an anti-inflammatory agent, could significantly influence inflammation in RA patients. Therefore, adding a lipid-lowering agent to standard medications in RA may be warranted and could decrease disease activity.
Clinical trial registration: The trial was registered at the Iranian Registry of Clinical Trials (Website: http://www.irct.ir, Irct ID: IRCT2015122425648N2).
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
References
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis
classification criteria: an American College of Rheumatology/European League Against Rheumatism
collaborative initiative. Arthritis Rheum. 2010; 62(9): 2569-81. doi: 10.1002/art.27584. PMID: 20872595.
Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and
micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Diabetes Care. 2002; 25(7): 1198-202. doi: 10.2337/diacare.25.7.1198. PMID: 12087019.
Bansback N, Ara R, Ward S, Anis A, Choi HK. Statin Therapy in Rheumatoid Arthritis.
Pharmacoeconomics. 2009; 27(1): 25-37. doi: 10.2165/00019053-200927010-00004. PMID: 19178122.
Barsante MM, Roffê E, Yokoro CM, Tafuri WL, Souza DG, Pinho V, et al. Anti-inflammatory and
analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol. 2005; 16(3):
-9. doi: 10.1016/j.ejphar.2005.05.005. PMID: 15970284.
Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, et al. Effects of high- dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid
arthritis: a pilot study. J Rheumatol. 2007; 34(7): 1459-64. PMID: 17552046.
Cush JJ, Weinblatt ME, Kavanaugh A. Rheumatoid Arthritis: Early Diagnosis and Treatment, 4E.
Professional Communications. 2010.
Ebringer A. Rheumatoid Arthritis and Proteus. Springer. 2011.
Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, et al. Exposure of atorvastatin is
unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced
myopathy. Clin Pharmacol Ther. 2006; 79(6): 532-9. doi: 10.1016/j.clpt.2006.02.014. PMID: 16765141.
Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology 12/E. McGraw-Hill Education.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances
the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Circulation. 2003; 108(13): 1560-6. doi: 10.1161/01.CIR.0000091404.09558.AF. PMID: 12975259.
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's Principles of Internal
Medicine, 18th Edition. McGraw-Hill Education. 2011.
Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, et al. Atorvastatin has an important
acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double- blind, placebo-controlled study. Am Heart J. 2005; 149(3): 451-7. doi: 10.1016/j.ahj.2004.07.041. PMID:
McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakova O, Ford I, et al. Trial of Atorvastatin in
Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;
(9426): 2015-21. doi: 10.1016/S0140-6736(04)16449-0. PMID: 15207950.
McInnes IB, Kim HY, Lee SH, Mandel D, Song YW, Connell CA, et al. Open-label tofacitinib and double- blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014; 73(1): 124- 31. doi: 10.1136/annrheumdis-2012-202442. PMID: 23482473.
Nikitina NM, Rebrov AP. [The use of atorvastatin in patients with rheumatoid arthritis with
hyperlipidemia]. Kardiologiia. 2009; 49(9): 21-6. PMID: 19772499.
Susekov AV, Rozhkova TA, Tripoten MI, Pogorelova OA, Kulev BD, Balakhonova TV, et al.
[Randomized FARVATER study. Part 2. Effect of atorvastatin on endothelial function, distensibility and
stiffness of vascular wall]. Kardiologiia. 2006; 47(2): 25-30. PMID: 17495819.
Wahane VD, Kumar VL. Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular
arthritis. Pharmacol Res. 2010; 61(4): 329-33. doi: 10.1016/j.phrs.2009.11.006. PMID: 19931618.
Yood RA. American College of Rheumatology Subcommittee on Rheumatoid Arthritis G. Guidelines for
the management of rheumatoid arthritis: 2002 update. 2002.
Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Müller GA. Anti-inflammatory effects of
atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J
Rheumatol. 2009; 38(4): 235-9. doi: 10.1080/03009740802572475. PMID: 19247848.
Kinderlerer AR, Steinberg R, Johns M, Harten SK, Lidington EA, Haskard DO, et al. Statin-induced
expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory
actions of statins in rheumatoid arthritis. Arthritis Res Ther. 2006; 8(4): 130. doi: 10.1186/ar2019. PMID:
, PMCID: PMC1779384.
Barsante MM, Roffê E, Yokoro CM, Tafuri WL, Souza DG, Pinho V, et al. Anti-inflammatory and
analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol. 2005; 516(3):
-9. doi: 10.1016/j.ejphar.2005.05.005. PMID: 15970284.
Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and
improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002;
(2): 563-8. doi: 10.1210/jcem.87.2.8249. PMID: 11836286.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
